MA30076B1 - Carbonylaminopyrrolopyrazoles servant de puissants inhibiteurs de kinases. - Google Patents
Carbonylaminopyrrolopyrazoles servant de puissants inhibiteurs de kinases.Info
- Publication number
- MA30076B1 MA30076B1 MA31060A MA31060A MA30076B1 MA 30076 B1 MA30076 B1 MA 30076B1 MA 31060 A MA31060 A MA 31060A MA 31060 A MA31060 A MA 31060A MA 30076 B1 MA30076 B1 MA 30076B1
- Authority
- MA
- Morocco
- Prior art keywords
- carbonylaminopyrrolopyrazoles
- kinases
- powerful inhibitors
- inhibitors
- formula
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- XPBFIMLMVNXIIB-UHFFFAOYSA-N 3-isocyanatopyrrolo[3,2-c]pyrazole Chemical class N1=CC=C2N=NC(N=C=O)=C21 XPBFIMLMVNXIIB-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101000987297 Homo sapiens Serine/threonine-protein kinase PAK 4 Proteins 0.000 abstract 1
- 102100027940 Serine/threonine-protein kinase PAK 4 Human genes 0.000 abstract 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 239000003909 protein kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Carbonylaminopyrrolopyrazoles servant de puissants inhibiteurs de kinases Des carbonylaminopyrrolopyrazoles de formule (I), des compositions comprenant ces composés et des méthodes pour leur utilisation sont proposés. Les composés préférés de formule (I) ont une activité comme inhibiteurs de protéine-kinases, y compris comme inhibiteurs de PAK4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75334905P | 2005-12-21 | 2005-12-21 | |
| US86493206P | 2006-11-08 | 2006-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA30076B1 true MA30076B1 (fr) | 2008-12-01 |
Family
ID=38189022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA31060A MA30076B1 (fr) | 2005-12-21 | 2008-06-20 | Carbonylaminopyrrolopyrazoles servant de puissants inhibiteurs de kinases. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7884117B2 (fr) |
| EP (1) | EP1979356B1 (fr) |
| JP (1) | JP4635089B2 (fr) |
| KR (1) | KR101029167B1 (fr) |
| AP (1) | AP2369A (fr) |
| AU (1) | AU2006327866B2 (fr) |
| BR (1) | BRPI0620354A2 (fr) |
| CA (1) | CA2634381C (fr) |
| CR (1) | CR10094A (fr) |
| CU (1) | CU23751B7 (fr) |
| DK (1) | DK1979356T3 (fr) |
| EA (1) | EA015513B1 (fr) |
| EC (1) | ECSP088558A (fr) |
| ES (1) | ES2435405T3 (fr) |
| GE (1) | GEP20104974B (fr) |
| HR (1) | HRP20130976T1 (fr) |
| IL (1) | IL191776A (fr) |
| MA (1) | MA30076B1 (fr) |
| ME (1) | ME00006B (fr) |
| MY (1) | MY151455A (fr) |
| NO (1) | NO20082482L (fr) |
| NZ (1) | NZ568692A (fr) |
| PL (1) | PL1979356T3 (fr) |
| PT (1) | PT1979356E (fr) |
| RS (2) | RS20080281A (fr) |
| WO (1) | WO2007072153A2 (fr) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL385265A1 (pl) * | 2008-05-23 | 2009-12-07 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej |
| BRPI0923225A2 (pt) | 2008-12-02 | 2016-10-04 | Chiralgen Ltd | metodo para sintese de acidos nucleicos modificados no atomo de fosforo |
| EP2451461A4 (fr) | 2009-07-06 | 2013-05-29 | Ontorii Inc | Nouveaux précurseurs d'acide nucléique et leurs méthodes d'utilisation |
| EP2937345B1 (fr) | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de la kinase raf de type ii |
| DK2620428T3 (da) * | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| BR112013012175A2 (pt) | 2010-11-17 | 2019-09-24 | Hoffmann La Roche | combinação, coadministração, uso e método |
| US8771682B2 (en) | 2011-04-26 | 2014-07-08 | Technische Universtität Dresden | Methods and compositions for reducing interleukin-4 or interleukin-13 signaling |
| CN107365339A (zh) | 2011-07-19 | 2017-11-21 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| JP6106685B2 (ja) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤 |
| HK1200093A1 (en) | 2012-03-16 | 2015-07-31 | 霍夫曼-拉罗奇有限公司 | Methods of treating melanoma with pak1 inhibitors |
| DK2872147T3 (da) | 2012-07-13 | 2023-02-20 | Wave Life Sciences Ltd | Fremgangsmåde til fremstilling af kirale oligonukleotider |
| SG11201500243WA (en) | 2012-07-13 | 2015-04-29 | Shin Nippon Biomedical Lab Ltd | Chiral nucleic acid adjuvant |
| WO2014010250A1 (fr) | 2012-07-13 | 2014-01-16 | Chiralgen, Ltd. | Groupe auxiliaire asymétrique |
| EP2909194A1 (fr) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de cycline-dépendante kinase 7 (cdk7) |
| US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
| USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| WO2015058126A1 (fr) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Composés hétéroaromatiques utiles dans le traitement de maladies prolifératives |
| AU2014337044A1 (en) | 2013-10-18 | 2016-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
| EP3095459A4 (fr) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Adjuvant d'acide nucléique chiral ayant un effet antitumoral et agent antitumoral |
| WO2015108046A1 (fr) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | Adjuvant d'acide nucléique chiral ayant une activité anti-allergique, et agent anti-allergique |
| EP3095461A4 (fr) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Adjuvant d'acide nucléique chiral possédant une activité d'induction d'immunité, et activateur d'induction d'immunité |
| EP3094728B1 (fr) | 2014-01-16 | 2022-03-09 | Wave Life Sciences Ltd. | Conception chirale |
| WO2015164614A1 (fr) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de janus kinase et leurs utilisations |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| US10131679B2 (en) | 2014-10-31 | 2018-11-20 | Ube Industries, Ltd. | Substituted dihydropyrrolopyrazole compound |
| US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| CA2986441A1 (fr) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Therapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases |
| AU2016281225B2 (en) * | 2015-06-15 | 2020-10-15 | Ube Corporation | Substituted dihydropyrrolopyrazole derivative |
| WO2017044858A2 (fr) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinases cycline-dépendantes |
| WO2017144546A1 (fr) | 2016-02-23 | 2017-08-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques pour le traitement d'un carcinome de rhinopharyngite |
| EP3810132A4 (fr) | 2018-06-25 | 2022-06-22 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinase de la famille taire et utilisations correspondantes |
| JP7530297B2 (ja) | 2018-11-14 | 2024-08-07 | Ｕｂｅ株式会社 | ジヒドロピロロピラゾール誘導体 |
| CN113164477A (zh) | 2018-12-14 | 2021-07-23 | 达纳-法伯癌症研究所股份有限公司 | C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途 |
| EP3902542A4 (fr) * | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de la kinase dépendante des cyclines 7 et leurs utilisations |
| WO2020212484A1 (fr) | 2019-04-17 | 2020-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions de traitement de troubles dépendants de il-1beta mediés par inflamasome nlrp3 |
| CN114981298B (zh) | 2019-12-12 | 2024-08-20 | 听治疗有限责任公司 | 用于预防和治疗听力损失的组合物和方法 |
| WO2021198511A1 (fr) | 2020-04-03 | 2021-10-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pour le traitement d'une infection par sars-cov-2 |
| WO2022008597A1 (fr) | 2020-07-08 | 2022-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et composition pharmaceutique pour le traitement de maladies infectieuses |
| WO2024261302A1 (fr) | 2023-06-22 | 2024-12-26 | Institut National de la Santé et de la Recherche Médicale | Inhibiteurs de nlrp3, inhibiteurs de pak1/2 et/ou inhibiteurs de caspase 1 pour le traitement de maladies monogéniques liées au rac2 |
| WO2025078334A1 (fr) | 2023-10-09 | 2025-04-17 | Institut National de la Santé et de la Recherche Médicale | Combinaison d'inhibiteurs de pak1 et d'inhibiteurs de clk pour prévenir la résistance à la chimiothérapie chez des patients souffrant de leucémie myéloïde aiguë |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2416527C (fr) * | 2000-08-10 | 2009-12-22 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles actifs en tant qu'inhibiteurs de kinase, leur procede de preparation et compositions pharmaceutiques les contenant |
| MXPA05000945A (es) | 2002-07-25 | 2005-05-16 | Pharmacia Italia Spa | Biciclo-pirazoles activos como inhibidores de la cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. |
| GB0229526D0 (en) | 2002-12-19 | 2003-01-22 | Astrazeneca Ab | Chemical compounds |
| UA81790C2 (uk) * | 2002-12-19 | 2008-02-11 | Фармация Италия С.П.А. | Заміщені піролопіразольні похідні як інгібітори кінази |
| WO2005030776A1 (fr) | 2003-09-23 | 2005-04-07 | Vertex Pharmaceuticals Incorporated | Derives de pyrazolopyrrole utilises en tant qu'inhibiteurs de proteines kinases |
| CA2593428C (fr) | 2005-01-10 | 2012-04-17 | Pfizer Inc. | Pyrrolopyrazoles, puissants inhibiteurs de kinases |
-
2006
- 2006-12-12 MY MYPI20082267 patent/MY151455A/en unknown
- 2006-12-12 CA CA2634381A patent/CA2634381C/fr not_active Expired - Fee Related
- 2006-12-12 ES ES06831731T patent/ES2435405T3/es active Active
- 2006-12-12 HR HRP20130976TT patent/HRP20130976T1/hr unknown
- 2006-12-12 JP JP2008546667A patent/JP4635089B2/ja not_active Expired - Fee Related
- 2006-12-12 BR BRPI0620354-0A patent/BRPI0620354A2/pt not_active IP Right Cessation
- 2006-12-12 GE GEAP200610777A patent/GEP20104974B/en unknown
- 2006-12-12 AP AP2008004506A patent/AP2369A/xx active
- 2006-12-12 DK DK06831731.2T patent/DK1979356T3/da active
- 2006-12-12 NZ NZ568692A patent/NZ568692A/en not_active IP Right Cessation
- 2006-12-12 RS RSP-2008/0281A patent/RS20080281A/sr unknown
- 2006-12-12 US US12/158,241 patent/US7884117B2/en not_active Expired - Fee Related
- 2006-12-12 PL PL06831731T patent/PL1979356T3/pl unknown
- 2006-12-12 AU AU2006327866A patent/AU2006327866B2/en not_active Ceased
- 2006-12-12 WO PCT/IB2006/003646 patent/WO2007072153A2/fr not_active Ceased
- 2006-12-12 RS RS20130498A patent/RS53029B/sr unknown
- 2006-12-12 KR KR1020087014963A patent/KR101029167B1/ko not_active Expired - Fee Related
- 2006-12-12 EP EP06831731.2A patent/EP1979356B1/fr active Active
- 2006-12-12 ME MEP-2008-8A patent/ME00006B/fr unknown
- 2006-12-12 EA EA200801291A patent/EA015513B1/ru not_active IP Right Cessation
- 2006-12-12 PT PT68317312T patent/PT1979356E/pt unknown
-
2008
- 2008-05-27 IL IL191776A patent/IL191776A/en not_active IP Right Cessation
- 2008-06-02 NO NO20082482A patent/NO20082482L/no not_active Application Discontinuation
- 2008-06-18 EC EC2008008558A patent/ECSP088558A/es unknown
- 2008-06-19 CU CU20080115A patent/CU23751B7/es active IP Right Grant
- 2008-06-20 MA MA31060A patent/MA30076B1/fr unknown
- 2008-06-20 CR CR10094A patent/CR10094A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN05208A1 (fr) | Composes aminoheteroaryliques servant d'inhibiteurs de proteine-kinases | |
| MY151455A (en) | Carbonylamino pyrrolopyrazoles, potent kinase inhibitors | |
| MA29141B1 (fr) | Pyrrolopyrazoles, servant de puissants inhibiteurs de kinases | |
| JO3181B1 (ar) | مشتقات كمحول ثاني الكيل البايردينيل - أحادي الفينيل كأنزيم ثنائي استرات الفوسفود | |
| ATE554087T1 (de) | Neue kinaseinhibitoren | |
| NO20070557L (no) | Ftalazinderivater som PARP-inhibitorer | |
| MXPA05013076A (es) | Compuestos de isoindolina-1-ona como inhibidores de cinasa. | |
| EP1675552A4 (fr) | Preparation d'azabenzimidazoles 1,6-disubstitues comme inhibiteurs de kinases | |
| NO20073140L (no) | Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser | |
| EA200800546A1 (ru) | Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk) | |
| NO20034289L (no) | N-(2-aryletyl)benzylaminer som antagonister av 5-HT6- reseptoren | |
| TN2010000052A1 (fr) | Derives de pyrazole et leur utilisation comme inhibiteurs de raf | |
| ATE430747T1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren | |
| EA201100749A1 (ru) | Производные пиридина и пиримидина в качестве ингибиторов фосфодиэстеразы 10 | |
| EA201170680A1 (ru) | Ингибиторы акт и p70 s6-киназы | |
| NO20076145L (no) | Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav | |
| EA201001481A1 (ru) | Производные третичного амина в качестве ингибиторов фосфодиэстеразы-4 | |
| EA201000618A1 (ru) | 5-цианотиенопиридины для лечения опухолей | |
| TW200621721A (en) | Methods of preparing indazole compounds | |
| TN2010000231A1 (fr) | Derives de pyrazole servant d'inhibiteurs de 5-lo | |
| MX2007013238A (es) | Derivados de fenilacetileno que tienen afinidad por el receptor mglur5. | |
| EA201000494A1 (ru) | Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4 | |
| MX2008001538A (es) | Aril piridinas y metodos para su uso. | |
| NO20080160L (no) | Mellomprodukter nyttige i syntesene av alkylkinolin og alkylkinazolin kinasemodulatorer og beslektede fremgangsmater for synteser | |
| MX2009012079A (es) | Compuestos heterociclicos condensados como inhibidores de proteina cinasas. |